Immunotoxins pp 255-277 | Cite as

Immunotoxins: Selection of cell-surface antigens and their corresponding monoclonal antibodies

  • Michael J. Bjorn
  • C. L. Villemez
Part of the Cancer Treatment and Research book series (CTAR, volume 37)


Immunotoxins (ITs) are complex molecules. To be effective, they must have a number of desirable features relating to the linker, the toxin component, the antibody component, and the target antigen, to name just a few. Other chapters in this volume have discussed linkers and toxins. This chapter will focus on target antigens and their corresponding monoclonal antibodies. Discussion will be limited primarily to ITs, defined as an antibody coupled to a protein toxin (including A chains and hemitoxins), although mention will also be made of antigen-toxin conjugates.


Transferrin Receptor Autologous Bone Marrow Transplantation Acanthamoeba Keratitis Acanthamoeba Castellanii Selective Killing 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Schneider, C., Sutherland, R., Newman, R., and Greaves, M. (1982) Structural features of the cell surface receptor for transferrin is recognized by the monoclonal antibody OKT9. J. Biol. Chem., 257, 8516–8522.PubMedGoogle Scholar
  2. 2.
    Omary, M.B., and Trowbridge, I.S. (1981) Biosynthesis of the human transferrin receptor in cultured cells. J. Biol. Chem., 256, 1288–1292.Google Scholar
  3. 3.
    McClelland, A., Kuhn, L.C., and Ruddle, F.H. (1984) The human transferrin receptor gene: Genomic organization and the complete primary structure of the receptor deduced from a cDNA sequence. Cell, 39, 267–274.PubMedCrossRefGoogle Scholar
  4. 4.
    Schneider, C., Owen, M.J., Banville, D., and Williams, J.G. (1984) Primary structure of human transferrin receptor deduced from the mRNA sequence. Nature, 311, 675–678.PubMedCrossRefGoogle Scholar
  5. 5.
    Stearne, P.A., Pietersz, G.A., and Goding, J.W. (1985) cDNA cloning of the murine transferrin receptor: Sequence of transmembrane and adjacent region. J. Immunol., 134, 3474–3479.PubMedGoogle Scholar
  6. 6.
    Larrick, J.W., and Cresswell, P. (1976) Modulation of cell surface iron transferrin receptors by cellular density and state of activation. J. Supramolec. Struct., 11, 579–586.CrossRefGoogle Scholar
  7. 7.
    Sutherland, R., Delia, D., Schneider, C., Newman, R., Kemshead, J., and Greaves, M. (1981) Ubiquitous cell-surface glycoprotein on tumor cells is proliferation-associated receptor for transferrin. Proc. Natl. Adad. Sci. USA, 78, 4515–4519.CrossRefGoogle Scholar
  8. 8.
    Gatter, K., Brown, G., Trowbridge, I.S., Woolston, R., and Mason, D.Y. (1983) Transferrin receptors in human tissues: Their distribution and possible clinical relevance. J. Clin. Pathol., 36, 539–545.PubMedCrossRefGoogle Scholar
  9. 9.
    Faulk, W.P., Hsi, B., and Stevens, P.J. (1980) Transferrin and transferrin receptors in carcinoma of the breast. Lancet, (Aug. 23), 390–392.Google Scholar
  10. 10.
    Shindelman, J.E., Ortmeyer, A.E., and Sussman, H.H. (1981) Demonstration of the transferrin receptor in human breast cancer tissue. Potential marker for identifying dividing cells. Int. J. Cancer, 44, 1301–1310.Google Scholar
  11. 11.
    Jefferies, W.A., Brandon, M.R., Hunt, S.V., Williams, A.F., Gatter, K.C., and Mason, D.Y. (1984) Transferrin receptor on endothelium of brain capillaries. Nature, 312, 162–163.PubMedCrossRefGoogle Scholar
  12. 12.
    Lebman, D., Trucco, M., Bottero, L., Lange, B., Pessano, S., and Rovera, G. (1982) A monoclonal antibody that detects expression of transferrin receptor in human erythroid precursor cells. Blood, 59, 671–678.PubMedGoogle Scholar
  13. 13.
    Lesley, J., Hyman, R., Schulte, R., and Trotter, J. (1984) Expression of transferrin receptor on human hematopoietic progenitors. Cell Immunol., 83, 14–25.PubMedCrossRefGoogle Scholar
  14. 14.
    Jefferies, W.A., Brandon, M.R., Williams, A.F., and Hunt, S.V. (1985) Analysis of lymphopoietic stem cells with a monoclonal antibody to the rat transferrin receptor. Immunology, 54, 333–341.PubMedGoogle Scholar
  15. 15.
    Octave, J., Schneider, Y., Crichton, R., and Trouet, A. (1981) Transferrin uptake by cultured rat embryo fibroblasts. The influence of temperature and incubation time, sub-cellular distribution and short-term kinetic studies. Eur. J. Biochem., 115, 611–618.PubMedCrossRefGoogle Scholar
  16. 16.
    Karin, M., and Mintz, B. (1981) Receptor-mediated endocytosis of transferrin in developmentally totipotent mouse teratocarcinoma stem cells. J. Biol. Chem., 256, 3245–3252.PubMedGoogle Scholar
  17. 17.
    Dickson, R.B., Hanover, J.A., Willingham, M.C., and Pastan, I. (1983) Prelysosomal divergence of transferrin and epidermal growth factor during receptor-mediated endocytosis. Biochemistry, 22, 5667–5674.PubMedCrossRefGoogle Scholar
  18. 18.
    Hopkins, C.R., and Trowbridge, I.S. (1983) Internalization and processing of transferrin and the transferrin receptor in human carcinoma A431 cells. Cell Biol., 97, 508–521.CrossRefGoogle Scholar
  19. 19.
    Willingham, M.C., and Pastan, I. (1985) Ultrastructural immunocytochemical localization of the transferrin receptor using a monoclonal antibody in human KB cells. J. Histochem. Cytochem., 33, 59–64.PubMedCrossRefGoogle Scholar
  20. 20.
    Pastan, I., Willingham, M.C., and FitzGerald, D.J. (1986) Immunotoxins. Cell, 47, 641–648.PubMedCrossRefGoogle Scholar
  21. 21.
    Trowbridge, I.S., and Domingo, D.L. (1981) Anti-transferrin receptor monoclonal antibody and toxin-antibody conjugates affect growth of human tumor cells. Nature, 294, 171–173.PubMedCrossRefGoogle Scholar
  22. 22.
    Lesley, J., Domingo, D.L., Schulte, R., and Trowbridge, I.S. (1984) Effect of an antimurine transferrin receptor-ricin A conjugate on bone marrow stem and progenitor cells treated in vitro. Exp. Cell Res., 150, 400–407.PubMedCrossRefGoogle Scholar
  23. 23.
    Ramakrishnan, S., and Houston, L.L. (1984) Inhibition of human acute lymphoblastic leukemia cells by immunotoxins: Potentiation by chloroquine. Science, 223, 58–61.PubMedCrossRefGoogle Scholar
  24. 24.
    Ramakrishnan, S., Uckun, F.M., and Houston, L.L. (1985) Anti-T-cell immunotoxins containing pokeweed anti-viral protein: Potential purging agents for human autologous bone marrow transplantation. J. Immunol., 135, 3616–3622.PubMedGoogle Scholar
  25. 25.
    Bjorn, M.J., Larrick, J., Piatak, M., and Wilson, K.J. (1984) Characterization of translational inhibitors from Phytolacca americana. Amino-terminal sequence determinations and antibody-inhibitor conjugates. Biochim. Biophys. Acta, 790, 154–163.PubMedCrossRefGoogle Scholar
  26. 26.
    Bjorn, M.J., Ring, D., and Frankel, A. (1985) Evaluation of monoclonal antibodies for the development of breast cancer immunotoxins. Cancer Res., 45, 1214–11221.PubMedGoogle Scholar
  27. 27.
    Bjorn, M.J., Groetsema, G., and Scalapino, L. (1986) Antibody-Pseudomonas exotoxin A conjugates cytotoxic to human breast cell lines in vitro. Cancer Res., 46, 3262–3267.PubMedGoogle Scholar
  28. 28.
    Pirker, R., FitzGerald, D.J., Hamilton, T.C., Ozols, R.F., Willingham, M.C., and Pastan, I. (1985) Anti-transferrin receptor antibody linked to Pseudomonas exotoxin as a model immunotoxin in human ovarian carcinoma cell lines. Cancer Res., 45, 751–757.PubMedGoogle Scholar
  29. 29.
    FitzGerald, D.J., Willingham, M.C., and Pastan, I. (1986) Antitumor effect of an immunotoxin made with Pseudomonas exotoxin in a nude mouse model of human ovarian cancer. Proc. Natl. Acad. Sci. USA, 83, 6627–6630.PubMedCrossRefGoogle Scholar
  30. 30.
    FitzGerald, D.J., Bjorn, M.J., Ferris, R.J., Winkelhake, J.L., Frankel, A.E., Hamilton, T.C., Ozolos, R.F., Willingham, M.C., and Pastan, I. (1987) Anti-tumor activity of an immunotoxin in a nude mouse mode of human ovarian cancer. Cancer Res., 47, 1407–1410.PubMedGoogle Scholar
  31. 31.
    FitzGerald, D.J., Trowbridge, I.S., Pastan, I., and Willingham, M.C. (1983) Enhancement of toxicity of anti-transferrin receptor antibody-Pseudomonas exotoxin conjugates by adenovirus. Proc. Natl. Acad. Sci. USA, 80, 4134–4136.PubMedCrossRefGoogle Scholar
  32. 32.
    Trowbridge, I.S., and Lopez, F. (1982) Monoclonal antibody to transferrin receptor blocks transferrin binding and inhibits human tumor cell growth in vitro. Proc. Natl. Acad. Sci. USA, 79, 1175–1179.PubMedCrossRefGoogle Scholar
  33. 33.
    Taetle, R., Castagnola, J., and Mendelsohn, J. (1986) Mechanisms of growth inhibition by anti-transferrin receptor monoclonal antibodies. Cancer Res., 46, 1759–1763.PubMedGoogle Scholar
  34. 34.
    Trowbridge, I.S., and Domingo, D.L. (1982) Prospects for the clinical use of cytotoxic monoclonal antibody conjugates in the treatment of cancer. Cancer Surveys, 1, 544–556.Google Scholar
  35. 35.
    Sauvage, C.A., Mendelsohn, J.C., Lesley, J.F., and Trowbridge, I.S. (1987) Effect of monoclonal antibodies that block transferrin receptor function on the in vivo growth of a syngeneic murine leukemia. Cancer Res., 47, 747–753.PubMedGoogle Scholar
  36. 36.
    Trowbridge, I.S., Lesley, J., and Schulte, R. (1982) Murine cell surface transferrin receptor: Studies with an anti-receptor monoclonal antibody. J. Cell. Physiol., 112, 403–410.PubMedCrossRefGoogle Scholar
  37. 37.
    Lesley, J.F., and Schulte, R.J. (1985) Inhibition of cell growth by monoclonal antitransferrin receptor antibodies. Mol. and Cell. Biol., 5, 1814–1822.Google Scholar
  38. 38.
    Gilliland, D.G., Steplewski, Z., Collier, R.J., Mitchell, K.F., Chang, T.H., and Koprowski, H. (1980) Antibody-directed cytotoxic agents: Use of monoclonal antibody to direct the action of toxin A chains to colorectal carcinoma cells. Proc. Natl. Acad. Sci. USA, 77, 4539–4543.PubMedCrossRefGoogle Scholar
  39. 39.
    Frankel, A.E., Ring, D.B., Tringale, F., and Hsieh-Ma, S.T. (1985) Tissue distribution of breast cancer-associated antigens defined by monoclonal antibodies. J. Biol. Resp. Modif., 4, 273–286.Google Scholar
  40. 40.
    Pirker, R., FitzGerald, D.J., Hamilton, T.C., Ozols, R.F., Laird, W., Frankel, A.E., Willingham, M.C., and Pastan, I. (1985) Characterization of immunotoxins active against ovarian cancer cell lines. J. Clin. Invest., 76, 1261–1267.PubMedCrossRefGoogle Scholar
  41. 41.
    Krolick, K.A., Yuan, D., and Vitetta, E.S. (1981) Specific killing of a human breast carcinoma cell line by a monoclonal antibody coupled to the A-chain of ricin. Cancer Immunol. Immunother., 12, 39–41.CrossRefGoogle Scholar
  42. 42.
    Canevari, S., Orlandi, R., Riparmonti, M., Tagliabue, E., Aguanno, S., Miotti, S., Menard, S., and Colnaghi, M.I. (1985) Ricin A chain conjugated with monoclonal antibodies selectively killing human carcinoma cells in vitro. J. Natl. Cancer Inst., 75, 831–839.PubMedGoogle Scholar
  43. 43.
    Monaco, M.E., Mack, J., Dugan, M.D., and Ceriani, R. (1986) An antibody-toxin conjugate directed against a human mammary cancer antigen. Ann. N.Y. Acad. Sci, 4645, 389–399.CrossRefGoogle Scholar
  44. 44.
    Coombes, R.C., Buckman, R., Forrester, J.A., Shepherd, V., O’Hare, M.J., Vincent, M., Powles, T.J., and Neville, A.M. (1986) In vitro and in vivo effects of a monoclonal antibody-toxin conjugate for use in autologous bone marrow transplantation for patients with breast cancer. Cancer Res., 46, 4217–4220.PubMedGoogle Scholar
  45. 45.
    Casellas, P., Brown, J.P., Gros, O., Hellstrom, I., Jansen, F.K., Poncelet, P., Ronucci, R., Vidal, H., and Hellstrom, K.E. (1982) Human melanoma cells can be killed in vitro by an immunotoxin specific for melanoma-associated antigen p97. Int. J. Cancer, 30, 437–443.CrossRefGoogle Scholar
  46. 46.
    Bumol, T.F., Wang, Q.C., Reisfeld, R.A., and Kaplan, N.O. (1983) Monoclonal antibody and an antibody-toxin conjugate to a cell surface proteoglycan of melanoma cells suppress in vivo tumor growth. Proc. Natl. Acad. Sci. USA, 80, 529–533.PubMedCrossRefGoogle Scholar
  47. 47.
    Spitler, L.E., del Rio, M., Khentigan, A., and Scannon, P. (1987) Therapy of patients with malignant melanoma using Xomazyme-mel, a monoclonal antimelanoma antibody-ricin A chain immunotoxin: Results of phase I trial. J. Cell. Biochem., 10B (supplement), 54.Google Scholar
  48. 48.
    Webb, K.S., Liberman, S.N., Ware, J.L., Walther, P.J. (1986) In vitro synergism between hybrid immunotoxins and chemotherapeutic drugs: Relevance to immunotherapy of prostate carcinoma. Cancer Immuno. Immunother, 21, 100–106.Google Scholar
  49. 49.
    Merriam, J.C., Lyon, H.S., and Char, D.H. (1984) Toxicity of a monoclonal F’(ab’)2: Ricin A conjugate for retinoblastoma in vitro. Cancer Res., 44, 3178–3183.PubMedGoogle Scholar
  50. 50.
    Tsukazaki, K., Hayman, E.G., and Ruoslahti, E. (1985) Effects of ricin A chain conjugates of monoclonal antibodies to human a-fetoprotein and placental alkaline phosphatase on antigen-producing cells in culture. Cancer Res., 45, 1834–1838.PubMedGoogle Scholar
  51. 51.
    Embleton, M.J., Byers, V.S., Lee, H.M., Scannon, P., Blackhall, N.W., and Baldwin, R.W. (1986) Sensitivity and selectivity of ricin toxin A chain-monoclonal antibody 79IT/36 conjugates against human tumor cell lines. Cancer Res., 46, 5524–5528.PubMedGoogle Scholar
  52. 52.
    Thiesen, H., Juhl, H., and Arndt, R. (1987) Selective killing of human bladder cancer cells by combined treatment with A and B chain ricin antibody conjugates. Cancer Res., 47, 419–423.PubMedGoogle Scholar
  53. 53.
    Bernhard, M.I., Foon, K.A., Oeltmann, T.N., Key, M.E., Hwang, K.M., Clarke, G.C., Christensen, W.L., Hoyer, L.C., Hanna, M.G., Jr., and Oldham, R.K. (1983) Guinea pig line 10 hepatocarcinoma model: Characterization of monoclonal antibody and in vivo effect of unconjugated antibody and antibody conjugated to diphtheria toxin A chain. Cancer Res., 43, 4420–4428.PubMedGoogle Scholar
  54. 54.
    Hwang, K.M., Foon, K.A., Cheung, P.H., Pearson, J.W., and Oldham, R.K. (1984) Selective antitumor effect on L10 hepatocarcinoma cells of a potent immunoconjugate composed of the A chain of abrin and a monoclonal antibody to a hepatoma-associated antigen. Cancer Res., 44, 4578–4586.PubMedGoogle Scholar
  55. 55.
    Levin, L.V., Griffin, T.W., Haynes, L.R., and Sedor, C.J. (1982) Selective cytotoxicity for a colorectal carcinoma cell line by a monoclonal anti-carcinoembryonic antigen coupled to the A chain of ricin. J. Biol. Resp. Modif., 1, 149–162.Google Scholar
  56. 56.
    Griffin, T.W, Haynes, L.R., and DeMartino, J.A. (1982) Selective cytotoxicity of a ricin A-chain-anti-carcinoembryonic antigen antibody conjugate for a human adenocarcinoma cell line. J. Natl. Can. Inst., 69, 799–805.Google Scholar
  57. 57.
    Goldenberg, D.M., DeLand, F., and Kim, E. (1978) Use of radio-labeled antibodies to carcinoembryonic antigen for the detection and localization of diverse cancers by external photoscanning. N Engl. J. Med., 258, 1384–1386.CrossRefGoogle Scholar
  58. 58.
    Roth, J.A., Ames, R.S., Byers, V., Lee, H.M., and Scannon, P.J. (1986) Monoclonal antibody 45–2D9 conjugated to the A chain of ricin is specificially toxic to c-Ha-rastransfected NIH 3T3 cells expressing gp74. J. Immunol., 136, 2305–2310.PubMedGoogle Scholar
  59. 59.
    Krolick, K.A., Villemez, C., Isakson, P., Uhr, J.W., and Vitetta, E.S. (1980) Selective killing of normal or neoplastic B cells by antibodies coupled to the A chain of ricin. Proc. Natl. Acad. Sci. USA, 77, 5419–5423.PubMedCrossRefGoogle Scholar
  60. 60.
    Oeltmann, T.N., and Forbes, J.T. (1981) Inhibition of mouse spleen cell function by diphtheria toxin fragment A coupled to anti-mouse Thy-1.2 and by ricin A chain coupled to anti-mouse IgM. Arch. Biochem. Biophys., 209, 362–370.PubMedCrossRefGoogle Scholar
  61. 61.
    Raso, V., and Griffin, R. (1981) Hybrid antibodies with dual specificity for the delivery of ricin to immunoglobulin-bearing target cells. Cancer Res., 41, 2073–2078.PubMedGoogle Scholar
  62. 62.
    Krolock, K.A., Uhr, J.W., Slavin, S., and Vitetta, E.S. (1982) In vivo therapy of a murine B cell tumor (BCL1) using antibody-ricin A chain immunotoxins. J. Exp. Med., 155, 1797–1809.CrossRefGoogle Scholar
  63. 63.
    Krolick, K.A., Uhr, J.W., and Vitetta, E.S. (1982) Selective killing of leukemia cells by antibody-toxin conjugates: Implications for autologous bone marrow transplantation. Nature, 295, 604–605.PubMedCrossRefGoogle Scholar
  64. 64.
    Vitetta, E.S., Cushley, W., and Uhr, J.W. (1983) Synergy of ricin A chain-containing immunotoxins and ricin B chain-containing immunotoxins in in vitro killing of neoplastic human B cells. Proc. Natl. Acad. Sci. USA, 80, 6332–6335.PubMedCrossRefGoogle Scholar
  65. 65.
    Muirhead, M., Martin, P.J., Torok-Storb, B., Uhr, J.W., and Vitetta, E.S. (1983) Use of an antibody-ricin A-chain conjugate to delete neoplastic B cells from human bone marrow. Blood, 62, 327–332.PubMedGoogle Scholar
  66. 66.
    Vitetta, E.S., and Uhr, J.W. (1985) Immunotoxins. Ann. Rev. Immunol., 3, 197–212.CrossRefGoogle Scholar
  67. 67.
    Marks, A., Baumal, R., Lei, M., Ahmad, A., and Liu, E. (1985) Inhibition of protein synthesis by monoclonal anti-idiotypic antibody-ricin A chain conjugates in MOPC315 myeloma cells. Anticancer Res., 5, 431–434.PubMedGoogle Scholar
  68. 68.
    Lowe, J.A., Ling, N.R., Forrester, J.A., Cumber, A.J., and Ross, W.C.J. (1985) Variants of lymphoid lines produced with ricin A-chain monoclonal antibody conjugates. J. Immunol. Meth., 76, 93–104.CrossRefGoogle Scholar
  69. 69.
    DeShambo, R.M., and Krolick, K.A. (1986) Selective in vitro inhibition of an antibody response to purified acetyl-choline receptor by using anti-idiotypic antibodies coupled to the A chain of ricin. J. Immunol., 137, 3135–3139.PubMedGoogle Scholar
  70. 70.
    Bregni, M., DeFabritiis, P., Raso, V., Greenberger, J., Lipton, J., Nadler, L., Rothstein, L., Ritz, J., and Bast, R.C., Jr. (1986) Elimination of clonogenic tumor cells from human bone marrow using a combination of monoclonal antibody ricin A chain conjugates. Cancer Res., 46, 1208–1213.PubMedGoogle Scholar
  71. 71.
    Fulton, R.J., Uhr, J.W., and Vitetta, E.S. (1986) The effect of antibody valency and lysosomotropic amines on the synergy between ricin A chain and ricin B chain-containing immunotoxins. J. Immunol., 136, 3103–3109.PubMedGoogle Scholar
  72. 72.
    Raso, V., Ritz, J., Basala, M., and Schlossman, S.F. (1982) Monoclonal antibody-ricin A chain conjugate selectively cytotoxic for cells bearing the common acute lymphoblastic leukemia antigen. Cancer Res., 42, 457–464.PubMedGoogle Scholar
  73. 73.
    Lambert, J.M., Senter, P.D., Yau-Young, A., Blattler, W.A., and Goldmacher, V.S. (1985) Purified immunotoxins that are reactive with human lymphoid cells. Monoclonal antibodies conjugated to the ribosome-inactivating proteins gelonin and the pokeweed antiviral proteins. J. Biol. Chem., 260, 12035–12041.PubMedGoogle Scholar
  74. 74.
    Uckun, F.M., Ramakrishnan, S., and Houston, L.L. (1985) Immunotoxin-mediated elimination of clonogenic tumor cells in the presence of human bone marrow. J. Immunol., 134, 2010–2016.PubMedGoogle Scholar
  75. 75.
    Uckun, F.M., Ramakrishnan, S., and Houston, L.L. (1985) Increased efficiency in selective elimination of leukemia cells by a combination of a stable derivative of cyclophosphamide and a human B-cell-specific immunotoxin containing pokeweed antiviral protein. Cancer Res., 45, 69–75.PubMedGoogle Scholar
  76. 76.
    Wiels, J., Junqua, S., Dujardin, P., Le Pecq, J., and Tursz, T. (1984) Properties of immunotoxins against a glycolipid antigen associated with Burkitt’s lymphoma. Cancer Res., 44, 129–133.PubMedGoogle Scholar
  77. 77.
    May, R.D., Vitetta, E.S., Moldenhauer, G., and Dorken, B. (1987) Selective killing of normal and neoplastic human B cells with anti-CD19- and anti-CD22-ricin A chain immunotoxins. Cancer Drug Delivery, 3, 261–272.CrossRefGoogle Scholar
  78. 78.
    Rennie, D.P., Wright, J., McGregor, A.M., Weetman, A.P., Hall, R., and Thorpe, P. (1983) An immunotoxin of ricin A chain conjugated to thyroglobulin selectively suppresses the anti-thyroglobulin antoantibody response. The Lancet, December 13, 1338–1340.CrossRefGoogle Scholar
  79. 79.
    Killen, J.A., and Lindstrom, J.M. (1984) Specific killing of lymphocytes that cause experimental autoimmune myasthenia gravis by ricin toxin-acetylcholine receptor conjugates. J. Immunol., 133, 2549–2553.PubMedGoogle Scholar
  80. 80.
    Olsberg, C.A., Mikiten, T.M., and Krolick, K.A. (1985) Selective in vitro inhibition of an antibody response of purified acetylcholine receptor by using antigen-ricin A chain immunotoxin. J. Immunol., 135, 3062–3067.PubMedGoogle Scholar
  81. 81.
    Volkman, D.J., Ahmad, A., Fauci, A.S., and Neville, D.M., Jr. (1982) Selective abrogation of antigen-specific human B cell responses by antigen-ricin conjugates. J. Exp. Med., 156, 634–639.PubMedCrossRefGoogle Scholar
  82. 82.
    Morimoto, C., Masuho, Y., Borel, Y., Steinberg, A.D., and Schlossman, S.F. (1983) Selective inhibition of anti-nucleoside-specific antibody production by nucleoside-ricin A conjugate. J. Immunol., 131, 1762–1764.PubMedGoogle Scholar
  83. 83.
    Youle, R.J., and Neville, D.M., Jr. (1980) Anti-Thy 1.2 monoclonal antibody linked to ricin is a potent cell-type-specific toxin. Proc. Natl. Acad. Sci. USA, 77, 5483–5486.PubMedCrossRefGoogle Scholar
  84. 84.
    Houston, L.L., and Nowinski, R.C. (1981) Cell-specific cytotoxicity expressed by a conjugate of ricin and murine monoclonal antibody directed against Thy 1.1 antigen Cancer Res., 41, 3913–3917.PubMedGoogle Scholar
  85. 85.
    Vallera, D.A., Youle, R.J., Neville, D.M., Jr., and Kersey, J.H. (1982) Bone marrow transplantation across major histocompatibility barriers. V. Protection of mice from lethal graft-vs.-host disease by pretreatment of donor cells with monoclonal anti-Thy-1.2 coupled to the toxin ricin. J. Exp. Med., 155, 949–954.PubMedCrossRefGoogle Scholar
  86. 86.
    Youle, R.J., and Neville, D.M., Jr. (1982) Kinetics of protein synthesis inactivation by ricin-anti-Thy 1.1 monoclonal antibody hybrids. Role of the ricin B subunit demonstrated by reconstitution. J. Biol. Chem., 257, 1598–1601.PubMedGoogle Scholar
  87. 87.
    Vallera, D.A., Youle, R.J., Neville, D.M., Jr., Soderling, C.B., and Kersey, J.H. (1983) Monoclonal antibody toxin conjugates for experimental graft-versus-host disease prophylaxis. Transplantation, 36, 73–80.PubMedCrossRefGoogle Scholar
  88. 88.
    Colombatti, M., Nabholz, M., Gros, O., and Bron, C. (1983) Selective killing of target cells by antibody-ricin A chain or antibody-gelonin hybrid molecules: Comparison of cytotoxic potency and use in immunoselection procedures. J. Immunol., 131, 3091–3095.PubMedGoogle Scholar
  89. 89.
    Ramakrishnan, S., and Houston, L.L. (1984) Comparison of the selective cytotoxic effects of immunotoxins containing ricin A chain or pokeweed antiviral protein and anti-Thy 1.1 monoclonal antibodies. Cancer Res., 44, 201–208.PubMedGoogle Scholar
  90. 90.
    Ramakrishnan, S., and Houston, L.L. (1984) Prevention of growth of leukemia cells in mice monoclonal antibodies directed against Thy 1.1 antigen disulfide linked to two ribosomal inhibitors: Pokeweed antiviral protein or ricin A chain. Cancer Res., 44, 1398–1404.PubMedGoogle Scholar
  91. 91.
    Thorpe, P.E., Brown, A.N., Bremmer, J.A., Jr., Foxwell, B.M., and Stirpe, F. (1985) An immunotoxin composed of monoclonal antibody anti-Thy 1.1 antibody and a ribosome-inactivating protein from Saponaria officinalis: Potent antitumor effects in vitro and in vivo. J. Natl. Cancer Inst., 75, 151–159.PubMedGoogle Scholar
  92. 92.
    Blakey, D.C., Wawrzynczak, E.J., Stirpe, F., and Thorpe, P.E. (1987) Antitumor activity of a panel of anti-Thy 1.1 immunotoxins made with different ribosome inactivating proteins. ULCA Symposium on Molecular and Cellular Biology, B. Bonavida and R.J. Collier, eds, in press.Google Scholar
  93. 93.
    Allison, J.P., McIntyre, B.W., Irvin, J., Bloch, D., and Kitto, B. (1983) Monoclonal antibody to tumor specific epitope of murine lymphoma cells: Use in characterization of antigen and in immunotherapy. Hybridoma and Cellular Immortality, B.H. Tom and J.P. Allison, eds. Plenum Pub. Corp., pp 201–219.Google Scholar
  94. 94.
    Thorpe, P.E., Mason, D.W., Brown, P.N., Simmonds, S.J., Ross, W.C., Cumber, A.J., and Forrester, J.A. (1982) Selective killing of malignant cells in a leukemic rat bone marrow using an antibody-ricin conjugate. Nature, 297, 594–596.PubMedCrossRefGoogle Scholar
  95. 95.
    Vallera, D.A., Ashe, R.C., Zanjani, E.D., Kersey, J.H., LeBien, T.W., Beverley, P.C., Neville, D.M., Jr., and Youle, R.J. (1983) Anti-T-cell reagents for human bone marrow transplantation. Ricin linked to three monoclonal antibodies. Science, 222, 512–515.PubMedCrossRefGoogle Scholar
  96. 96.
    Kernan, N.A., Knowles, R.W., Burnes, M.J., Broxmeyer, H.F., Lu, L., Lee, H.M., Kawahata, R.T., Scannon, P.J., and Dupont, B. (1984) Specific inhibition of in vitro lymphocyte transformation by an anti-pan T cell (gp67) ricin A chain immunotoxin. J. Immunol., 133, 137–146.PubMedGoogle Scholar
  97. 97.
    Stong, R.C., Youle, R.J., and Vallera, D.A. (1984) Elimination of clonogenic T-leukemic cells from human bone marrow using anti-Mr 65,000 protein immunotoxins. Cancer Res., 44, 3000–3006.PubMedGoogle Scholar
  98. 98.
    Stong, R.C., Uckun, F., Youle, R.J., Kersey, J.H., and Vallera, D.A. (1985) Use of multiple T cell-directed intact ricin immunotoxins for autologous bone marrow transplantation. Blood, 66, 627–635.PubMedGoogle Scholar
  99. 99.
    Casellas, P., Canat, X., Fauser, A.A., Gros, O., Laurent, G., Poncelet, P., and Jansen, F.K. (1985) Optimal elimination of leukemic T cells from human bone marrow with T101-ricin-A-chain immunotoxin. Blood, 65, 269–297.Google Scholar
  100. 100.
    Douay, L., Gorin, N.C., Lopez, M., Casellas, P., Liance, M.C., Jansen, F.K., Voisin, G.A., Baillou, C., Laporte, J.P., Najman, A., and Duhamel, G. (1985) Evidence for absence of toxicity of T101 immunotoxin on human hematopoietic progenitor cells prior to bone marrow transplantation. Cancer Res., 45, 438–441.PubMedGoogle Scholar
  101. 101.
    Leonard, J.E., Wang, Q., Kaplan, N.O., and Royston, I. (1985) Kinetics of protein synthesis inactivation in human T-lymphocytes by selective monoclonal antibody-ricin conjugates. Cancer Res., 45, 5263–5269.PubMedGoogle Scholar
  102. 102.
    Uckun, F.M., Stong, R.C., Youle, R.J., and Vallera, D.A. (1985) Combined ex vivo treatment with immunotoxins and mafosfamid: A novel immunotherapeutic approach for elimination of neoplastic T cells from autologous marrow grafts. J. Immunol., 134, 3504–3515.PubMedGoogle Scholar
  103. 103.
    Weil-Hillman, G., Runge, W., Jansen, F.K., and Vallera, D.A. (1985) Cytotoxic effect of anti-Mr 67,000 protein immunotoxins on human tumors in a nude mouse model. Cancer Res., 45, 1328–1336.PubMedGoogle Scholar
  104. 104.
    Weil-Hillman, G., Uckun, F.M., Manske, J.M., and Vallera, D.A. (1987) Combined immunochemotherapy of human solid tumors in nude mice. Cancer Res., 47, 579–585.PubMedGoogle Scholar
  105. 105.
    Laurent, G., Kuhlein, E., Cassellas, P., Canat, X., Carayon, P., Poncelet, P., Corell, S., Rigal, F., and Jansen, F.K. (1986) Determination of sensitivity of fresh leukemia cells to immunotoxins. Cancer Res., 46, 2289–2294.PubMedGoogle Scholar
  106. 106.
    Laurent, G., Pris, J., Farcet, J., Carayon, P., Blythman, H., Casellas, P., Poncelet, P., and Jansen, F.K. (1986) Effects of therapy with T101 ricin A-chain immunotoxin in two leukemia patients. Blood, 67, 1680–1687.PubMedGoogle Scholar
  107. 107.
    Press, O.W., Vitetta, E.S., Farr, A.G., Hansen, J.A., and Martin, P.J. (1986) Evaluation of ricin A chain immunotoxins directed against human T-cells. Cell Immun., 102, 10–20.CrossRefGoogle Scholar
  108. 108.
    Youle, R.J., Uckun, F.M., Vallera, D.A., and Colombatti, M. (1986) Immunotoxins show rapid entry of diphtheria toxin but not ricin via the T3 antigen. J. Immunol., 136, 93–98.PubMedGoogle Scholar
  109. 109.
    Martin, P.J., Hansen, J.A., and Vitetta, E.S. (1985) A ricin A chain-containing immunotoxin that kills human T lymphocytes in vitro. Blood, 66, 908–912.PubMedGoogle Scholar
  110. 110.
    Colombatti, M., Greenfield, L., and Youle, R.J. (1986) Cloned fragments of diphtheria toxin linked to T cell-specific antibody identifies regions of B chain active in cell entry. J. Biol. Chem., 261, 3030–3035.PubMedGoogle Scholar
  111. 111.
    Seon, B.K. (1984) Specific killing of human T-leukemia cells by immunotoxins prepared with ricin A chain and monoclonal anti-human T-cell leukemia antibodies. Cancer Res., 44, 259–264.PubMedGoogle Scholar
  112. 112.
    Depper, J.M., Leonard, W.J., Kronke, M., Waldmann, T.A., and Greene, W.C. (1984) Augmented T cell growth factor receptor expression in HTLV-1-infected human leukemic T cells. J. Immunol., 133, 1691–1695.PubMedGoogle Scholar
  113. 113.
    Uchiyama, T., Broder, S., and Waldmann, T A (1981) A monoclonal antibody (anti-Tac) reactive with activated and functionally mature T cells. J. Immunol., 126, 1393–1397.PubMedGoogle Scholar
  114. 114.
    FitzGerald, D.J., Waldmann, T.A., Willingham, M.C., and Pastan, I. (1984) Pseudomonas exotoxin-anti-Tac cell specific immunotoxin active against cells expressing the human T cell growth factor receptor. J. Clin. Invest., 74, 966–971.PubMedCrossRefGoogle Scholar
  115. 115.
    Kronke, M., Depper, J.M., Leonard, W.J., Vitetta, E.S., Waldmann, T.A., and Greene, W.C. (1985) Adult T cell leukemia: A potential target for ricin-A-chain immunotoxins. Blood, 65, 1416–1421.PubMedGoogle Scholar
  116. 116.
    Kronke, M., Schlick, E., Waldmann, T.A., Vitetta, E.S., and Greene, W.C. (1986) Selective killing of human T-lymphotropic virus-1 infected leukemic T-cells by monoclonal anti-interleukin 2 receptor antibody-ricin A chain conjugates: Potentiation by ammonium chloride and monensin. Cancer Res., 46, 3295–3298.PubMedGoogle Scholar
  117. 117.
    Pastan, I., FitzGerald, D., Willingham, M.C., and Waldmann, T. (1986) Use of Pseudomonas toxin and ricin A to construct immunotoxins directed against adult T cell leukemia and ovarian cancer. J. Cell Biochem., 10B (supplement), 54.Google Scholar
  118. 118.
    Nakahara, K., Kaplan, D., Bjorn, M., and Fathman, C.G. (1985) The effectiveness of anti-Ia-Immunotoxins in the suppression of MLR. Transplantation, 42, 205–211.CrossRefGoogle Scholar
  119. 119.
    Shizuru, J.A., Ramakrishnan, S., Hunt, T., Merrell, R.C., and Fathman, C.G. (1986) Inhibition of rat mixed lymphocyte pancreatic islet cultures with anti-Ia immunotoxins. Transplantation, 42, 660–666.PubMedCrossRefGoogle Scholar
  120. 120.
    John, D.T., (1982) Primary amebic meningoencephalitis and the biology of Naegleria fowleri. Ann. Res. Microb., 36, 101–123.CrossRefGoogle Scholar
  121. 121.
    Seidel, J.S., Harmatz, P., Visvesvara, G.S., Cohen, A., Edwards, J., and Turner, J. (1982) Successful treatment of primary amoebic meningoencephalitis. New Engl. J. Med., 306, 346–348.PubMedCrossRefGoogle Scholar
  122. 122.
    Martinez, A.J. (1982) Acanthamoebiasis and immunosuppression. J. Neuropath. Exp. Neurol., 41, 548–557.PubMedCrossRefGoogle Scholar
  123. 123.
    Visvesvara, G.A., Mirra, S.S., Brandt, F.H., Moss, D. M., Mathews, H.V., and Martinez, A.J. (1983) Isolation of two strains of Acanthamoeba castellanii from human tissue and their pathogenicity and isoenzyme profiles. J. Clin. Microbiol., 18, 1405–1412.PubMedGoogle Scholar
  124. 124.
    Hanssens, M., de Jonckheere, J.F., and de Meunynck, C.H. (1985) Acanthamoeba keratitis — a clinicopathological case report. Inter. Opthal., 7, 203–213.CrossRefGoogle Scholar
  125. 125.
    Hirst, L.W., Green, W.R., Merz, W., Kaufmann, C., Visvesvara, G.S., Jensen, A., and Howard, M. (1984) Management of acanthamoeba keratitis — a case report and review of literature. Ophthal., 91, 1105–1111.Google Scholar
  126. 126.
    Byers, T.J. (1979) Growth, reproduction and differentiation in acanthamoeba. Int. Rev. Cyto., 61, 283–337.CrossRefGoogle Scholar
  127. 127.
    Howell, M.D., and Villemez, C.L. (1983) Toxicity of ricin, diphtheria toxin and alphamanitin for Acanthamoeba castellanii. J. Parasit., 70, 918–923.CrossRefGoogle Scholar
  128. 128.
    Villemez, C.L., and Carlo, P.L. (1984) Preparation of an immunotoxin for Acanthamoeba castellanii. Biochem. Biophys. Res. Com., 125, 25–29.PubMedCrossRefGoogle Scholar
  129. 129.
    Villemez, C.L., Russell, M.A., and Carlo, P.L. (1984) Mouse IgG1 heterogeneity: Variable binding of monoclonal IgG1 antibodies to protein A-sepharose. Mol. Immunol., 21, 993–998.PubMedCrossRefGoogle Scholar
  130. 130.
    Villemez, C.L., Carlo, P.L., and Russell, M.A. (1985) Differentiation in Acanthamoeba castellanii is induced by specific monoclonal antibodies. J. Cell. Biochem., 29, 373–379.PubMedCrossRefGoogle Scholar
  131. 131.
    Villemez, C.L., Russell, M.A., Barbieri, L., Stirpe, F., Irvin, J.D., and Robertus, J.D. (1986) Toxins for protozoan immunotoxins. UCLA Symp. Mol. Cell. Biol., 45, in press.Google Scholar

Copyright information

© Kluwer Academic Publishers 1988

Authors and Affiliations

  • Michael J. Bjorn
  • C. L. Villemez

There are no affiliations available

Personalised recommendations